Intellia Therapeutics Announces Fourth Quarter and Full-Year 2020 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Intellia Therapeutics (NTLA) Misses Q4 EPS by 9c, Revenues Miss
February 25, 2021 7:39 AM ESTIntellia Therapeutics (NASDAQ: NTLA) reported Q4 EPS of ($0.69), $0.09 worse than the analyst estimate of ($0.60). Revenue for the quarter came in at $6.6 million versus the consensus estimate of $14.09 million.
Intellias achievements in 2020 reflect important progress on both our full-spectrum strategy and our mission to deliver... More
